Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer.

Herrmann, Christina

Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer. [electronic resource] - Oncology 2007 - 335-9 p. digital

Publication Type: Journal Article

1423-0232

10.1159/000134477 doi


Adult
Aged
Aged, 80 and over
Antineoplastic Agents--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Capecitabine
Cohort Studies
Deoxycytidine--administration & dosage
Disease Progression
Drug Administration Schedule
Female
Fluorouracil--administration & dosage
Humans
Male
Middle Aged
Organoplatinum Compounds--administration & dosage
Oxaliplatin
Palliative Care
Pancreatic Neoplasms--drug therapy
Prognosis
Survival Rate
Time Factors
Gemcitabine